2026 Medicare Physician Fee Schedule, Part 3: Maximizing and Protecting Your 340B Program

In the final installment of a three-part series with VMG Health, host Jeff Wurzburg is joined by Elizabeth Burrows, Managing Director in VMG's Health Revenue Management Practice, to discuss the 340B drug pricing program — a critical but often underutilized revenue source for covered entities. Elizabeth covers how qualifying organizations can maximize 340B revenue, the strategic case for in-house pharmacies, compliance essentials including audit preparedness and database accuracy, and key trends to watch in 2026 — including the potential rebate model shift, manufacturer restrictions, and the implications of TrumpRx on 340B pricing.